Bioabsorbable coating with tunable hydrophobicity
a bioabsorbable coating and hydrophobic technology, applied in the field of organic chemistry, polymer science, material science, etc., can solve the problems of late stent thrombosis, occlude the conduit, and intimal flap formation or torn arterial linings which can collapse,
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0109]A composition was prepared by adding poly(L-lactide-co-ε-caprolactone) (0.12 gm) in chloroform (4.6848 g) and trichloroethane (1.17 g) in a tightly closed glass bottle. The mixture was stirred at 250 rpm for 2 hours. Everolimus (0.0245 g) was added to the reaction mixture. The reaction mixture further stirred at 500 rpm for 2 minutes. The first composition is applied onto the stent and dried to form a drug-polymer layer.
[0110]The composition is applied onto the stent by any conventional method, for example, by spraying or dipping. A primer layer (e.g., the above formulation without the therapeutically active substance) can be optionally applied on the surface of the bare stent prior to the application of the drug-polymer layer. The drug to polymer wt / wt ratio is 1:5. The drug dose is from about 100 microgram / cm2. The drug reservoir layer coating thickness is 6 um.
example 2
[0111]A composition was prepared by adding poly(L-lactide-co-ε-caprolactone) (0.12 gm) in chloroform (4.67 g) and trichloroethane (1.17 g) in a tightly closed glass bottle. The mixture was stirred at 250 rpm for 2 hours. Everolimus (0.0408 g) was added to the reaction mixture. The reaction mixture further stirred at 500 rpm for 2 minutes. The first composition is applied onto the stent and dried to form a drug-polymer layer.
[0112]The composition is applied onto the stent by any conventional method, for example, by spraying or dipping. A primer layer (e.g., the above formulation without the therapeutically active substance) can be optionally applied on the surface of the bare stent prior to the application of the drug-polymer layer. The drug to polymer wt / wt ratio is 1:3. The drug dose is from about 100 microgram / cm2. The drug reservoir layer coating thickness is 4 um.
example 3
[0113]A composition was prepared by adding poly(L-lactide-co-trimethylene carbonate) (0.06 gm) in trichloroethane (2.928 g) in a tightly closed glass bottle. The mixture was stirred at 250 rpm for 2 hours. Everolimus (0.01224 g) was added to the reaction mixture. The reaction mixture further stirred at 500 rpm for 2 minutes. The first composition is applied onto the stent and dried to form a drug-polymer layer.
[0114]The composition is applied onto the stent by any conventional method, for example, by spraying or dipping. A primer layer (e.g., the above formulation without the therapeutically active substance) can be optionally applied on the surface of the bare stent prior to the application of the drug-polymer layer. The drug to polymer wt / wt ratio is 1:5. The drug dose is from about 100 microgram / cm2. The drug reservoir layer coating thickness is 6 um.
PUM
| Property | Measurement | Unit |
|---|---|---|
| average molecular weight | aaaaa | aaaaa |
| thickness | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More